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Abstract
Metformin, an oral insulin-sensitizing drug, is actively transported into cells by organic cation transporters (OCT) 1, 2, and 3
(encoded by SLC22A1, SLC22A2,o rSLC22A3), which are tissue specifically expressed at significant levels in various organs
such as liver, muscle, and kidney. Because metformin does not undergo hepatic metabolism, drug-drug interaction by
inhibition of OCT transporters may be important. So far, comprehensive data on the interaction of proton pump inhibitors
(PPIs) with OCTs are missing although PPIs are frequently used in metformin-treated patients. Using in silico modeling and
computational analyses, we derived pharmacophore models indicating that PPIs (i.e. omeprazole, pantoprazole,
lansoprazole, rabeprazole, and tenatoprazole) are potent OCT inhibitors. We then established stably transfected cell lines
expressing the human uptake transporters OCT1, OCT2, or OCT3 and tested whether these PPIs inhibit OCT-mediated
metformin uptake in vitro. All tested PPIs significantly inhibited metformin uptake by OCT1, OCT2, and OCT3 in a
concentration-dependent manner. Half-maximal inhibitory concentration values (IC50) were in the low micromolar range (3–
36 mM) and thereby in the range of IC50 values of other potent OCT drug inhibitors. Finally, we tested whether the PPIs are
also transported by OCTs, but did not identify PPIs as OCT substrates. In conclusion, PPIs are potent inhibitors of the OCT-
mediated metformin transport in vitro. Further studies are needed to elucidate the clinical relevance of this drug-drug
interaction with potential consequences on metformin disposition and/or efficacy.
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Introduction
Metformin (1,1-dimethylbiguanide) is an oral insulin-sensitizing
agent commonly used either alone or in combination with other
antihyperglycemic drugs in patients with type 2 diabetes [1]. Based
on various population-based analyses, prescription of metformin in
patients with type 2 diabetes increased by about 50% in European
countries [2–5].
The glucose-lowering effect of metformin is largely attributable
to inhibition of hepatic gluconeogenesis, and additionally, insulin-
stimulated glucose uptake into skeletal muscle cells and adipocytes
is increased by metformin [1]. Recently, it has been shown that
organic cation transporters (OCTs) are crucial for the uptake of
metformin [6–10] and these membrane transport proteins are
expressed at significant levels in metformin target tissues such as
liver, muscle, and adipose tissue [10–13]. Data from OCT1
knockout mice [6,9] as well as from healthy volunteers carrying
OCT1 variants [9,14] clearly indicate an alteration of metformin
disposition and subsequent consequences for plasma glucose levels.
Since metformin does not undergo hepatic metabolism [15,16],
drug-drug interaction by inhibition of OCT transporters might be
important. Because OCT1 is expressed in human liver [10,11],
alteration of hepatic metformin uptake may be assumed, thereby
resulting in poor response to metformin treatment due to reduced
glucose-lowering effects. Otherwise, drug-drug interaction with
OCT2, which is expressed in proximal tubule epithelial cells [17],
would probably increase systemic disposition of metformin by
reduced renal clearance. Recently, a strong inhibiting effect of
repaglinide and rosiglitazone on OCT1-mediated metformin
transport as well as of several drugs on OCT2-mediated metfor-
min transport in vitro has been reported [18–20]. Clinically,
concomitant use of the potent OCT2 inhibitors cimetidine and
verapamil [21] in cisplatin-treated patients resulted in a lower risk
for cisplatin-related nephrotoxicity [22] since the antitumor drug
cisplatin is an OCT2 substrate [23,24]. This clinical observation is
supported by animal data, clearly demonstrating that cimetidine-
related inhibition of the OCT2 transporter alters cisplatin uptake
in the kidney [25,26]. These examples suggest that OCT-mediated
drug-drug interactions appear to be clinically relevant.
Hundreds of xenobiotics including drugs potentially inhibiting
OCTs were tested in the past and several new inhibitors have been
identified [19,21,27]. However, systematic data regarding the
important drug class of proton pump inhibitors (PPIs) are still
missing although PPIs are frequently used in metformin-treated
patients with metabolic syndrome and cardiovascular diseases.
Moreover, gastroesophageal reflux disease (GERD) is commonly
seen in patients with type 2 diabetes [28,29] and PPIs are the
drugs of best choice in treatment of GERD [30].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22163The aim of the present study was to investigate systematically in
vitro the drug-drug interaction potential of PPIs with OCTs. We
first used in silico pharmacophore modeling to assess the inhibitory
potential of PPIs. We then generated cell lines stably expressing
recombinant human OCT1 (encoded by the SLC22A1 gene),
OCT2 (SLC22A2), or OCT3 (SLC22A3) to experimentally confirm
the inhibitory potential of PPIs on OCT-mediated metformin
transport. Finally, we assessed whether PPIs are transported by
OCTs. Altogether, we identified PPIs as potent inhibitors of OCT-
mediated metformin transport.
Results
Pharmacophore Model Generation
Pharmacophore models were constructed for all 3 OCTs. For
this, the 15 most potent inhibitors of OCT1, OCT2, or OCT3 were
included as training compounds to test whether the PPIs
omeprazole, pantoprazole, lansoprazole, rabeprazole, and tenato-
prazoleareOCTinhibitors(FigureS1).Thisligand-basedapproach
revealed an OCT1 pharmacophore comprising 1 hydrophobic
interaction site and 2 H-bond acceptor sites, an OCT2 model
comprising 2 hydrophobic interaction sites and 1 H-bond acceptor
site, and an OCT3 model comprising 1 hydrophobic interaction
site, 2 H-bond acceptor sites, and 1 H-bond donor site (Figure 1,
Table S1). Moreover, Figure 1 shows the relative molecular
dimensions of the pharmacophore feature points. The OCT1
pharmacophore appears to have the smallest dimensions, followed
by the OCT2 and the OCT3 pharmacophore.
For all 5 PPIs high pharmacophore fit values were calculated
(Table S2) and each PPI occupies all the pharmacophore features
that were found to be relevant for a certain pharmacophore (Figure
S2). Both results suggest that the PPIs are potent OCT inhibitors.
Characterization of OCT-expressing HEK Cells
In order to test inhibitory potencies of PPIs in vitro, we stably
transfected HEK cells with cDNAs encoding human OCT1,
OCT2, or OCT3. All 3 transfected cell lines showed time-
dependent uptake of the prototypic substrate TEA (Figure 2A)
and of metformin (Figure 2B). Metformin uptake was almost
completely absent in the presence of 2 mM MPP, indicating that
metformin uptake is largely due to recombinantly expressed OCT
transporters. As expected by these uptake experiments, the
recombinant OCT proteins were detected in the plasma membrane
of HEK cells by immunofluorescence microscopy (Figure 2C) using
isoform-specific antibodies characterized previously [10,31]. None
of the isoform-specific antibodies resulted in staining of vector-
transfected control HEK cells. The respective recombinant OCT
protein was detected in membrane fractions from OCT-expressing
HEK cells, but not in control cells, at molecular masses of ,70 kDa
(Figure 2D). The band at ,50 kDa in membrane fractions from
OCT1-expressingHEKcellsprobablyreflectsanisoformwithalow
extent of glycosylation, because after deglycosylation only one band
at ,45 kDawasdetectable(notshown).Theband seen at,65 kDa
using the anti-OCT2 antibody can be most likely explained by a
cross-reactivity of the antibody with a protein endogenously
expressed in the HEK cells because it is detected in OCT2-
expressing as well as in control HEK cells. This protein appears to
be detectable only under SDS denaturing conditions since in the
immunostaining experiments staining was only observed in OCT2-
expressing but not in control HEK cells.
Inhibition of OCT-mediated Metformin Transport by PPIs
Inhibition of OCT-specific metformin uptake by PPIs was
measured within the linear uptake phase of each transporter. Each
PPI significantly inhibited OCT-mediated metformin transport in
a concentration-dependent manner (Figure 3). The calculated
IC50 values are in the low micromolar range (3–36 mM; Table 1).
Regarding the benzimidazoles omeprazole, pantoprazole, lanso-
prazole, and rabeprazole, the latter one has the highest inhibitory
potency towards all 3 OCTs. Omeprazole, pantoprazole, and
lansoprazole tended to inhibit OCT2 more potently than OCT1
or OCT3. For the imidazopyridine tenatoprazole, similar IC50
values were obtained for all 3 OCTs.
Relationship between Physicochemical Properties of PPIs
and OCT Inhibition Potency
Because the 5 PPIs are very similar in structure, their OCT
inhibition potency might be explained by a single physicochemical
property. We, therefore, analyzed whether 7 computed physico-
chemical properties of PPIs (molecular weight, topological polar
surface area [TPSA], H-bond acceptor count, rotatable bond
count, tautomer count, heavy atom count, and the lipophilicity
parameter ‘‘calculated log octanol/water partition coefficient’’
[ClogP], Table S3) correlated with the inhibitory potency towards
OCTs. In univariate analyses, no significant correlation between
the IC50 values and these physicochemical properties were
observed (Table S4).
We next determined the relationship between the IC50 values
and these 7 physicochemical parameters by partial least square
(PLS) analysis. OCT1 inhibition was best explained by a two-
component model. The cumulative Q
2 value of 0.74 indicated a
good predictive power of the model and the R
2 value of 0.99
indicated that variation in the IC50 values was largely modeled by
the two components. For comparison, a one-component model
resulted in a Q
2 value of 0.19 explaining 89% of variation in the
IC50 values. The variable influence on projection (VIP) function
was then used to identify the physicochemical parameters most
relevant for explaining the IC50 values in the two-component
model. The number of H-bond acceptor sites (VIP=1.61) and the
ClogP value (VIP=1.15) contributed most to the two-component
model for OCT1 inhibition. For OCT2 and OCT3 inhibition, the
PLS analysis resulted in one-component models. Although the R
2
values were 0.53 for OCT2 and 0.56 for OCT3, the Q
2 values
were ,0 for both suggesting that the models cannot predict IC50
values for OCT2 and OCT3.
Evaluation of PPIs as Transport Substrates of OCTs
In order to assess whether the 5 PPIs are transported by OCTs,
PPI uptake by OCT-expressing HEK cells was compared with that
by controlcells after 1 and 5 minof incubation (Figure 4). Noneof the
PPIsaccumulatedtohigherlevelsintheOCT-expressingcellsthanin
control cells indicating that PPIs are not transported by OCTs.
Discussion
With the recent advances in the understanding of the role of
drug transporters in pharmacokinetics it has become critical to
elucidate drug-drug interactions that are rooted in transporters.
Drug transporters can be generally classified as either uptake or
efflux transporters characterizing whether they facilitate drug
entry into a cell or efflux out of a cell.
In the present paper we focused on the uptake transporter
proteins OCT1, OCT2, and OCT3 since the antidiabetic drug
metformin is a substrate for each and there is already evidence that
e.g. the antidiabetics repaglinide or rosiglitazone [18] as well as H2
receptor antagonists (e.g. cimetidine, [19]) inhibit OCT function.
Since PPIs are frequently used in patients with type 2 diabetes, we
combined in silico pharmacophore modeling with subsequent in
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22163vitro assays to systematically investigate drug-drug interaction of
metformin with omeprazole, pantoprazole, lansoprazole, rabepra-
zole, which are FDA-approved agents, and the non-FDA-labeled
PPI tenatoprazole (benatoprazole, TU-199).
The pharmacophore models described for OCT1 [32–34] and
OCT2 [19,35] share a hydrophobic interaction site and a positive
ionizable site. The pharmacophore models of the present study are
in line with these models in having at least 1 hydrophobic
interaction site as well (Figure 1). The lack of a positive ionizable
site in our models is probably due to the fact that many of the
compounds selected for the training sets [19,27,36] are neutral at
pH 7.4. Our pharmacophore models predict PPIs to be very potent
Figure 1. Pharmacophore models of OCT1, OCT2, and OCT3. Ligand-based pharmacophore models were generated with igandScout using
the 15 most potent OCT1, OCT2, or OCT3 inhibitors as training set and 5 PPIs (omeprazole, pantoprazole, lansoprazole, rabeprazole, tenatoprazole) as
test set. The 5 PPIs are mapped to each pharmacophore model. Yellow sphere: hydrophobic interaction site (Hy), red sphere: H-bond acceptor site
(HBA), green sphere: H-bond donor site (HBD); 2 stacked blue rings: aromatic ring. On the right, the centers of the pharmacophore features are
redrawn and the interfeature distances are shown in A ˚ngstroms.
doi:10.1371/journal.pone.0022163.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22163Figure 2. Characterization of HEK cells stably transfected with cDNAs encoding human OCT1, OCT2, or OCT3. A. Time-dependent
uptake of 100 mM TEA, a prototypic OCT substrate, by HEK-OCT1, HEK-OCT2, or HEK-OCT3. Data are means 6 SD of 3 determinations. B. Time-
dependent uptake of 5 mM metformin by HEK-OCT1, HEK-OCT2, or HEK-OCT3 and assessment of non-specific uptake by performing uptake studies in
the presence of 2 mM unlabeled MPP, a high-affinity OCT substrate. Data are means 6 SD of 3 determinations. C. Confocal laser scanning
micrographs of HEK-OCT1, HEK-OCT2, and HEK-OCT3 cells after incubation with the OCT isoform-specific antisera KEN, KEK, and CGR, respectively
[10,31]. Bars, 20 mm. D. Immunoblot analyses of membrane fractions from HEK-OCT1, HEK-OCT2, and HEK-OCT3 cells in comparison with those from
vector-transfected control cells (HEK-Co) using the OCT isoform-specific antisera KEN, KEK, and CGR, respectively.
doi:10.1371/journal.pone.0022163.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22163Figure 3. Inhibition of OCT-mediated metformin uptake by proton pump inhibitors. Uptake of 5 mM[
14C]metformin was measured after
5 min (OCT1, OCT3) or 5 sec (OCT2) to remain within the linear uptake phase of each transporter. OCT-specific metformin uptake was obtained by
subtracting metformin uptake in the presence of 2 mM unlabeled MPP from that in its absence. OCT-specific metformin uptake in the presence of
different concentrations of omeprazole, pantoprazole, lansoprazole, rabeprazole, or tenatoprazole was then calculated as percentage of that in the
absence of the respective PPI (100% uninhibited). Data points are the means 6 SE of 3 individual experiments, with 3 parallel measurements
performed in each individual experiment. Lines result from direct fits of the Hill equation to the data points.
doi:10.1371/journal.pone.0022163.g003
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their hydrophobic features and presence of H-bond acceptor sites.
In order to validate the data of the in silico pharmacophore
modeling, we generated cell systems stably expressing recombinant
human OCT1, OCT2, or OCT3. All 3 transfected HEK cell lines
expressed functionally active organic cation transporters as demon-
strated by time-dependent TEA and metformin uptake (Figure 2A
and B), which are both well-established substrates of OCTs
(reviewed in [21]). Consistent with these functional data, the
recombinant OCT proteins were detected in the plasma membrane
of the OCT-expressing HEK cells (Figure 2C) as well as in
membrane fractions fromthesecells (Figure 2D) asexpected [10,31].
The most striking result of our study was a potent inhibition of
metformin uptake transport by all five PPIs for all 3 OCT proteins
tested (OCT1, OCT2, and OCT3) with IC50 values in the low
micromolar range, similar to calculated total PPI concentrations in
portal venous blood (Figure 3, Table 1). Moreover, we could
clearly show that none of these PPIs are substrates for the 3 OCT
transport proteins (Figure 4). The fact that drugs are potent OCT
inhibitors without being substrates, is in agreement with results
obtained for several other compounds (reviewed in ref. [21]).
Moreover, OCT1- and OCT3-mediated metformin uptake
appears to be activated by low concentrations of selected PPIs
(OCT1: by rabeprazole; OCT3: by tenatoprazole, pantoprazole,
rabeprazole; Figure 3), which is in line with previous observations
reported for carvedilol and OCT2-mediated metformin uptake
[37] but also for other uptake transporters (e.g. OATP1B3) and
inhibitors (e.g. rosiglitazone) [18]. However, underlying molecular
mechanisms are currently unknown.
Given the role of OCT1 for metformin action [9] and of OCT2
for renal secretion of metformin [8], efforts have been made to
identify physicochemical parameters that may predict whether a
compound inhibits the OCT transporters. One study showed that a
positive charge at pH 7.4 and a high lipophilicity (ClogP ,3.5) are
the main properties of potent OCT1 inhibitors [27]. The PLS
analysis revealed that the ClogP value likewise appears to be a
relevant factor for explaining OCT1 inhibition by the 5 PPIs. For
OCT2,one study alsoidentified the ClogPvalue as aprincipalfactor
for potent inhibition [35], while in another study the TPSA value
was predictive for inhibition [19]. However, neither the ClogP value
nor the TPSA value are apparently predictive for OCT2 or OCT3
inhibition by PPIs. It therefore remains unclear which physico-
chemical parameters determine the inhibition potency of PPIs
towards OCT2 and OCT3. Another physicochemical parameter,
i.e. the charge at pH 7.4 that was identified as a relevant property of
OCT1 inhibitors [27], is apparently not sufficient for predicting a
compound’sinhibitionpotencytowardsOCTssincePPIsareneutral
at pH 7.4 and it has been shown that several other OCT inhibitors
are likewise not positively charged (e.g. prazosin, amsacrine,
phenoxybenzamine, lamivudine, azidothymidine).
Currently, to the best of our knowledge no interaction studies in
healthy volunteers and/or patients exist elucidating pharmacoki-
netic and/or –dynamic consequences of a combined therapy of
metformin and PPIs. Although it is difficult to predict clinical
consequences based on in vitro data there are some issues
supporting such an assumption.
Since OCT1 and OCT3 are expressed in the plasma membrane
of human hepatocytes, skeletal muscle cells, and adipocytes
[10,12,13,31], an inhibition potential of OCT function by PPIs
may abolish the glucose-lowering effect of metformin. This
assumption is corroborated by the observation that OCT1/3-
mediated metformin uptake into murine hepatocytes [9], human
adipocytes [13] or human skeletal muscle cells [12] is significantly
reduced by known OCT inhibitors such as quinidine or
cimetidine. Similarly, the activating effect of metformin on
AMP-activated protein kinase is altered [9,12,13].
Moreover, certain genotypes may directly affect the inhibition
potential of a drug, a mechanism which is increasingly recognized
[38]. OCT1 pharmacogenetics and drug-drug interaction for
metformin uptake and selected OCT1 inhibitors (e.g. verapamil or
amitriptylin) have recently been reported by in vitro experiments
[39]. Interestingly, an increased sensitivity to drug inhibition was
observed for OCT variants, particularly for those with reduced
function. While the glucose-lowering effect of metformin is
impaired either in healthy volunteers [9] or in diabetic patients
[40] carrying OCT1 variants with reduced function [14], no data
are currently available with respect to PPI co-medication. Since
generally only 60% of metformin-treated patients with type 2
diabetes do respond well [41], it might be possible that, clinically,
PPIs are a yet unrecognized factor for insufficient metformin
response due to a transporter-mediated drug-drug interaction via
OCT transport proteins.
Taken together, we identified PPIs as an important drug class
inhibiting OCT-mediated metformin transport. Moreover, our
present work underscores the impact of in silico pharmacophore
modeling since these computational data have been confirmed by
our experimental studies using transfected cell lines, which express
functionally active OCTs. Additionally, this newly recognized in
vitro drug-drug interaction warrants further clinical studies to
elucidate the in vivo relevance in metformin-treated patients
regarding drug disposition and/or pharmacodynamic consequenc-
es.
Table 1. Pharmacokinetic data of PPIs in humans and IC50 values of OCT-mediated metformin transport as determined in the
present study.
PPI
Dosage
(mg)
Dosage
(mmol)
Cmax
(mM)
Calculated Cport.vn.
(mM)
IC50 OCT1
(mM)
IC50 OCT2
(mM)
IC50 OCT3
(mM)
Omeprazole 20 58 1.8 (ref. [51]) 5.4 15.763.8 6.762.1 22.062.2
Pantoprazole 40 104 5.5 (ref. [52]) 12.0 30.868.8 2.860.9 22.965.2
Lansoprazole 30 81 2.7 (ref. [53]) 7.8 35.865.8 9.563.8 3.161.3
Rabeprazole 20 56 1.2 (ref. [54]) 4.7 3.061.7 5.760.5 3.060.8
Tenatoprazole 40 116 10 (ref. [55]) 17.2 23.367.1 20.367.2 14.762.4
PPI dosage and maximal total PPI concentration in the systemic circulation (Cmax) were from the indicated references. The maximal total PPI concentration in the portal
venous blood (Cport.vn) was calculated according to equation 1 in ref. [56]. For each PPI, 3 individual experiments were performed and within an individual experiment,
metformin uptake at a given PPI concentration was obtained from 3 parallel measurements. IC50 values were calculated for each individual experiment and are given as
means 6 SE.
doi:10.1371/journal.pone.0022163.t001
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Pharmacophore Model Generation
Pharmacophore models for OCT1, OCT2, and OCT3 were
generated with LigandScout (version 3.01, Inte:Ligand, Vienna,
Austria; ref. [42,43]) using the ligand-based strategy. With this
strategy, the pharmacophore model is derived from a set of ligands
in the absence of a macromolecule structure. This approach
searches for a common feature pattern that is shared in an active
ligand set and considers the conformational flexibility of the
Figure 4. Evaluation of proton pump inhibitors as transport substrates of OCTs. Intracellular accumulation of 10 mM[
14C]omeprazole,
10 mM[
14C]pantoprazole, 5 mM lansoprazole, 5 mM rabeprazole, or 5 mM tenatoprazole by vector-transfected control HEK cells (white bars) or OCT-
expressing HEK cells (black bars) was measured after 1 or 5 min of incubation. Data are means 6 SD of 3 determinations.
doi:10.1371/journal.pone.0022163.g004
OCT Transporters and Proton Pump Inhibitors
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22163ligands. All LigandScout parameters were kept default and models
were generated with the Fast calculation setting and a maximal
number of 75 conformations. For the OCT1 pharmacophore, the
training set consisted of the 10 most potent inhibitors as based on
IC50 values (5–17 mM) reported by Ahlin et al. [27]. Moreover, the
nucleotide reverse transcriptase inhibitors (NRTIs) lamivudine,
abacavir, tenofovir, azidothymidine, and emtricitabine were
included in the training set since they were recently identified to
interact with OCTs with high-affinity (IC50 values in the low
nanomolar range; [44]). The OCT2 pharmacophore model was
constructed with the 10 most potent inhibitors described by Zolk et
al. [19] (IC50 values from 6–25 mM) and the NRTIs as training
compounds. Because for OCT3 no comprehensive inhibition
analysis is available, compounds with the lowest IC50 values (0.8–
20 mM) were included from several studies (compiled from ref.
[21]), as well as the NRTIs. The PPIs omeprazole, pantoprazole,
lansoprazole, rabeprazole, and tenatoprazole were included for
each pharmacophore model generation as test compounds.
Cartesian coordinates and tolerance radii of chemical features of
the pharmacophore models were exported in xyz file format.
Cartesian coordinates were then imported into PyMOL (version
1.3, Schroedinger LLC, Portland, OR), which was used to
measure interfeature distances.
Chemicals and Antibodies
[
14C]Tetraethyl ammonium (TEA, MBq?mmol
21) and
[
14C]metformin hydrochloride (4074 MBq?mmol
21) were from
PerkinElmer (Rodgau, Germany) and Hartmann Analytic
(Braunschweig, Germany), respectively. [
14C]Omeprazole (470
MBq?mmol
21) and [
14C]pantoprazole (550 MBq?mmol
21) were
generously supplied by Byk Gulden (Konstanz, Germany) as
described [45]. Pantoprazole, rabeprazole, and tenatoprazole were
from Sequoia Research Products Ltd. (Pangbourne, UK). All
other chemicals, including G418 (geneticin), hygromycin, omep-
razole, and lansoprazole were from Sigma-Aldrich (Taufkirchen,
Germany) or Merck (Darmstadt, Germany) at the highest grade
available. Generation and use of the isoform-specific polyclonal
antisera directed against human OCT1 (KEN), OCT2 (KEK), or
OCT3 (CGR) have been described previously [10,31].
Cloning of Human OCTs and Generation of Stably
Transfected HEK Cell Lines
SLC22A1 cDNA and SLC22A2 cDNA had been PCR-amplified
from human liver and kidney, respectively, as reported elsewhere
and cDNAs were provided by the German Cancer Research
Center [31]; the study and the use of the tissue were approved by
the institutional review board of the German Cancer Center,
Heidelberg, Germany. Since the data were analyzed anonymous-
ly, and tissues were left-over samples from diagnostic procedures,
written informed consent had not been required and obtained.
IRB specifically waived the need for consent due to the fact the
human tissue material used was fully anonymized. SLC22A3
cDNA was amplified using SLC22A3-TrueClone (Origene,
Rockville, MD, USA) as the template. SLC22A1 cDNA was
cloned into the expression vector pcDNA3.1/Hygro(-) (Invitrogen,
Darmstadt, Germany), SLC22A2 and SLC22A3 cDNA into
pcDNA3.1(+) (Invitrogen). Each transporter cDNA was sequenced
and the respective deduced amino acid sequence was identical to
the published reference protein sequence (OCT1: NP_003048.1;
OCT2: NP_003049.2; OCT3: NP_068812.1). The human
embryonic kidney 293 (HEK) cell line was obtained from the
American Type Culture Collection. HEK cells were grown in
DMEM (Sigma) supplemented with 10% fetal bovine serum
(Sigma), 100 U?ml
21 penicillin, and 100 mg?ml
21 streptomycin
(Lonza, Basel, Switzerland) at 37uC and 5% CO2. HEK cells were
transfected with Metafectene Pro (Biontex, Mu ¨nchen, Germany).
Selection of clones stably expressing OCT1 was carried out with
0.5 mg?ml
21 hygromycin as described [31]. Similarly, clones
stably expressing OCT2 or OCT3 were selected with 800
mg?ml
21 G418. HEK cells stably transfected with the empty
pcDNA3.1(+) vector served as controls (HEK-Co). Cells were
incubated with 5 mM butyrate 24 h before use to increase protein
levels of recombinant transporters.
Immunolocalization Analyses
Transfected HEK cells were grown for 2 days on glass slides and
fixed with methanol at 220uC for 10 min. Cells were then
incubated with the primary antibodies and subsequently the
Alexa488-conjugated goat anti-rabbit secondary antibody (1:300,
Invitrogen/Molecular Probes) for 1 h as described [10]. Primary
antibodies were diluted in PBS as follows: KEN antiserum (against
OCT1) 1:300, KEK antiserum (against OCT2) 1:100, CGR
antiserum (against OCT3) 1:100. Images were taken with a
confocal laser scanning microscope (TCS NT Confocal System,
Leica Microsystems, Wetzlar, Germany).
Immunoblot Analyses
Membrane fractions were prepared from transfected HEK cells
as described [10] and stored at 280uC. Prior to immunoblotting,
membrane fractions were denatured for 30 min at 37uCi n
Laemmli sample buffer and separated on 10% SDS/polyacryl-
amide gels. Immunoblotting was performed essentially as de-
scribed [10]. Primary antibodies were incubated with the
nitrocellulose membranes for 1 h at room temperature at the
following dilutions: KEN antiserum 1:3000, KEK antiserum
1:2000, CGR antiserum 1:3000. Membranes were developed with
enhanced chemoluminescence detection solution (Supersignal
WestDura, Pierce, Rockford, IL, USA) and chemoluminescence
was measured with a charged-coupled device camera (Fuji LAS-
1000, Raytest, Straubenhardt, Germany). In some cases, mem-
brane fractions were deglycosylated with peptide N-glycosidase F
(EC 3.5.1.52) according to the manufacturer’s instructions (New
England BioLabs, Ipswich, MA) and then subjected to gel
electrophoresis.
Metformin and PPI Transport Studies
HEK cells (400000 cells/well) were seeded into 24-well cell
culture plates (Greiner Bio-One, Frickenhausen, Germany) and
grown for48 h.Cell adherencewasimprovedbycoatingplateswith
poly-L-lysine (Biochrom AG, Berlin, Germany) prior to cell plating.
All uptake studies were carried out at 37uC as described [31]. For
uptake measurements, cells were firstly washed with uptake buffer
(145 mM NaCl, 5 mM hydroxyethylpiperazine ethanesulfonic
acid, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM glucose,
pH 7.4, [46]) prewarmed to 37uC. Uptake was initiated by
replacing this solution with uptake buffer containing 5 mM
[
14C]metformin, 100 mM[
14C]TEA, 10 mM[
14C]omeprazole, or
10 mM[
14C]pantoprazole. Uptake was stopped at indicated time
points by removing the uptake buffer and immediately washing the
cells 3 times with ice-cold uptake buffer. Cells were lysed with 0.2%
SDS and intracellular radioactivity was determined by liquid
scintillation counting (Hidex 300SL TDCR liquid scintillation
counter, Turku, Finland). For measuring inhibition of OCT-
mediated metformin uptake by PPIs, 5 mM[
14C]metformin uptake
was measured in the presence of different PPI concentrations and
stopped after 5 min (OCT1, OCT3) or 5 sec (OCT2).
For determination of intracellular accumulation of unlabeled
lansoprazole, rabeprazole, and tenatoprazole, cells were incubated
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washed three times with ice-cold uptake buffer and twice with ice-
cold phosphate-buffered saline. Cells were harvested by scraping
them off in 500 ml 0.1 M sodium carbonate buffer (pH 9.3) :
methanol 4:1 (v/v) and then transferred into Eppendorf tubes. Cells
were disrupted by three cycles of shock freezing/thawing (liquid
nitrogen, 37uC water bath) and further by ultra-sonification, three
times 3 sec, at 4uC. Disrupted cell solutions were centrifuged 5 min
(15000 g) at 4uC and supernatants were transferred into Eppendorf
tubes and stored at 220uC for analytic determination of the PPIs.
Protein content of lysed cells was determined in 25-ml aliquots
using the bicinchoninic acid assay as described [31].
Determination of Lansoprazole, Rabeprazole, and
Tenatoprazole
Lansoprazole, rabeprazole, and tenatoprazole were determined
by LC-MS using omeprazole as internal standard similar to a
method described for omeprazole [47]. An Agilent Series 1100 LC-
MSD system (Agilent, Waldbronn, Germany) with binary pump,
degasser, autosampler and mass selective detector equipped with an
electrospray ion source was used. Chromatographic separation was
achieved on a ProntoSil AQ, C18 column (3 mm i.d. x 150 mm,
particle size 3 mm, Bischoff, Leonberg, Germany) at a flow rate of
0.5 ml?min
21. Gradient runs with the mobile phases (A) 10 mM
ammonium acetate in water and (B) acetonitrile were programmed
as described previously [47]. Electrospray parameters were as
follows: capillary voltage 4000 V, drying gas flow 9.5 l?min
21
nitrogen, drying gas temperature 350uC, and nebulizer pressure 30
psig (207 kPa gauge). The mass spectrometer was operated in the
selected ion monitoring mode using the respective MH
+ ions, m/z
370 for lansoprazole, m/z 360 for rabeprazole, m/z 347 for
tenatoprazole, and m/z 346 for the internal standard omeprazole.
The fragmentor was set at 80 V for lansoprazole, rabeprazole and
omeprazole, and at 60 V for tenatoprazole.
Calibration samples were prepared in 0.1 M sodium carbonate
buffer pH 9.3 : methanol 4:1 (v/v) containing 1 mMo m e p r a z o l ea s
internal standard, in the concentration range 2.5 to 250 nM for
lansoprazole and rabeprazole, and from 5 to 250 nM for
tenatoprazole. Calibration samples were worked up as the samples,
and analyzed together with the unknown samples. Calibration curves
based on internal standard calibration were obtained by weighted (1/
x
2) linear regression for the peak area ratio of the analyte to the
internal standard against the amount of the analyte. The concentra-
tion in unknown samples was obtained from the regression line.
Calculation of IC50 Values and Correlation with
Physicochemical Properties
OCT-specific metformin uptake was obtained by subtracting
metformin uptake in the presence of 2 mM unlabeled 1-methyl-4-
phenylpyridinium (MPP) from that in its absence. MPP was used
because it is transported by all 3 OCTs with high-affinity (Km of
OCT1: 15–32 mM; Km of OCT2: 3–19 mM; Km of OCT3: 47–
83 mM;reviewedinref.[21]).OCT-specificmetformin uptakeinthe
presence of a PPI was then calculated as percentage of that in the
absence of the respective PPI (100% uninhibited). For each PPI
concentration, 3 individual experiments each with 3 parallel
measurements were performed. Apparent IC50 values for inhibi-
tion of metforminuptake byPPIs werecalculated for each individual
experiment by fitting the values to the Hillequation using GraphPad
Prism 4 (GraphPad Software Inc., La Jolla, CA, USA). Values in
Table1aregivenasthemeans6SEofthe3individualexperiments.
The 2 physicochemical parameters ‘‘calculated octanol/water
partition coefficient’’ (ClogP) and ‘‘charge at pH 7.4’’ were
calculated using MarvinView (version 5.4.1.1, ChemAxon Ltd.,
Budapest, Hungary). Seven other computed physicochemical
properties (molecular weight, topological polar surface area [TPSA],
H-bond donor count, H-bond acceptor count, rotatable bond count,
tautomer count, heavy atom count) were from the publicly available
PubChem Compound database (http://www.ncbi.nlm.nih.gov/
pccompound; ref. [48]). TPSA estimation and H-bond donor/
acceptor classification follow refs. [49] and [50], respectively.
For the analysis of the relationship between physicochemical
properties of PPIs and IC50 values, the 7 parameters molecular
weight, ClogP, TPSA, H-bond acceptor count, rotatable bond
count, tautomer count, and heavy atom count were included,
because the 2 parameters ‘‘charge at pH 7.4’’ and ‘‘H-bond donor
count’’ did not vary among the PPIs. For univariate analysis, the
Pearson correlation coefficient (R) and P values (two-tailed) were
calculated with GraphPad Prism 4. Normality of data was
confirmed by the Kolmogorov-Smirnov test. Statistical signifi-
cance was defined as P,0.05. Multivariate analyses were
performed with the Excel-based add-in tool XLSTAT (version
2011.2.05; Addinsoft, Paris, France) using the partial least square
analysis module. The 7 physicochemical parameters molecular
weight, ClogP, TPSA, H-bond acceptor count, rotatable bond
count, tautomer count, and heavy atom count were included as
quantitative descriptive x values and the IC50 values as
quantitative dependent y values. The R
2 value indicates how
much of variation of the IC50 values is explained by the
components. The quality of the fit is estimated by the Q
2 value.
AQ
2.0 indicates that the model has a better predictive power
than no model.
Supporting Information
Figure S1 Molecular structures of the 5 tested PPIs.
(TIF)
Figure S2 Structural formula of the 5 PPIs with those chemical
features marked that were found by LigandScout to be relevant for
the OCT1, OCT2, or OCT3 pharmacophore model.
(TIF)
Table S1 Chemical feature coordinates and tolerance radii (in
A ˚ngstroms) found by LigandScout for the pharmacophore models
of OCT1, OCT2, and OCT3.
(DOC)
Table S2 Pharmacophore fit values of training sets and PPIs as
test set.
(DOC)
Table S3 Physicochemical properties of the tested PPIs.
(DOC)
Table S4 Relationship of physicochemical properties of the
tested PPIs and IC50 values of OCT1, OCT2, and OCT3 as
determined by univariate analysis.
(DOC)
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